

RANBAXY LABORATORIES LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended 31 March 2013

(Rupees in millions, except share data, per share data and if otherwise stated)

PART I

Sr. No.	Particulars	(Unaudited) Quarter ended 31 March 2013	(Audited) Quarter ended 31 December 2012	(Unaudited) Quarter ended 31 March 2012	(Audited) Year ended 31 December 2012
1	Income from operations				
	(a) Sales				
	- Within India (net of excise duty)	5,629.10	5,476.43	5,045.10	22,031.54
	- Outside India (refer to note 1)	7,649.67	8,537.84	13,057.18	39,092.89
	Net sales (net of excise duty)	13,278.77	14,014.27	18,102.28	61,124.43
	(b) Other operating income	537.59	400.96	562.44	1,911.01
	Total income from operations (net)	13,816.36	14,415.23	18,664.72	63,035.44
2	Expenses				
	(a) Cost of materials consumed	4,086.05	4,089.23	3,638.19	15,286.61
	(b) Purchases of stock-in-trade	1,906.89	1,906.38	1,940.02	8,090.01
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (refer to note 3)	(392.07)	(99.64)	109.44	(492.45)
	(d) Employee benefits expense (refer to note 4)	2,458.01	2,634.86	2,516.28	10,195.89
	(e) Depreciation, amortisation and impairment expense	452.93	463.94	468.73	1,861.61
	(f) Claims and contractual expense	22.64	506.06	2,244.92	3,842.89
	(g) Other expenses	5,319.12	5,709.54	4,589.90	20,118.78
	(h) Foreign exchange loss/ (gain) others, net	96.96	544.34	(1,299.50)	1,388.84
	Total expenses	13,950.53	15,754.71	14,207.98	60,292.18
3	(Loss)/ profit from operations before other income, finance costs and exceptional items (1-2)	(134.17)	(1,339.48)	4,456.74	2,743.26
4	Other income	523.26	671.09	536.91	2,395.98
5	Profit/ (loss) from ordinary activities before finance costs and exceptional items (3+4)	389.09	(668.39)	4,993.65	5,139.24
6	Finance costs (refer to note 9)	506.04	1,342.87	168.50	2,969.82
7	(Loss)/ profit from ordinary activities after finance costs but before exceptional items (5-6)	(116.95)	(2,011.26)	4,825.15	2,169.42
8	Exceptional items				
	- Gain/ (loss) on foreign currency option derivatives, net (other than loans) (refer to note 5)	818.42	(1,798.94)	3,447.16	(412.05)
	- Product recall	-	(2,370.20)	-	(2,370.20)
	- Provision for other-than-temporary diminution in the value of non-current investment in a subsidiary	-	-	-	(1,030.00)
9	Profit/ (loss) from ordinary activities before tax (7+8)	701.47	(6,180.40)	8,272.31	(1,642.83)
10	Tax (benefit)/ expense, net	-	(19.44)	-	(19.44)
11	Net profit/ (loss) for the period (9-10)	701.47	(6,160.96)	8,272.31	(1,623.39)
12	Paid - up equity share capital (Face value of Rs. 5 each)	2,115.03	2,114.57	2,110.16	2,114.57
13	Reserves excluding Revaluation Reserves as per Balance Sheet				17,095.10
14	Earnings/ (loss) per share (Rs.) - not annualised				
	Basic	1.66	(14.59)	19.62	(3.85)
	Diluted	1.66	(14.59)	19.58	(3.85)

See accompanying notes to the standalone unaudited financial results

PART II

Select information for the quarter ended 31 March 2013

Sr. No.	Particulars	Quarter ended 31 March 2013	Quarter ended 31 December 2012	Quarter ended 31 March 2012	Year ended 31 December 2012
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding #				
	- Number of shares	145,437,363	145,239,372	144,707,624	145,239,372
	- Percentage of shareholding	34.38%	34.34%	34.29%	34.34%
2	Promoters and promoter group shareholding				
	a) Pledged / encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-
	b) Non - encumbered				
	- Number of shares	268,711,323	268,711,323	268,711,323	268,711,323
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	63.52%	63.54%	63.67%	63.54%

Aggregate public shareholding as defined under Clause 40A of the Listing Agreement (excludes shares held by Promoters and Promoter Group Shareholding and Global Depository Shares)

Particulars	Quarter ended 31 March 2013
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	5
Disposed off during the quarter	5
Remaining unresolved at the end of the quarter	Nil



RANBAXY LABORATORIES LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended 31 March 2013

(Rupees in millions, except share data, per share data and if otherwise stated)

Notes:

- 1 Sales outside India include significant sales relating to First-To-File (FTF) products in the United States of America ("USA"). Further, pursuant to the accounting policy followed by the Company, sales outside India for all periods presented include transfer pricing adjustments with its subsidiaries for materials already supplied to them (including supplied in earlier periods), determined on the basis of significant judgment and estimates.
- 2 The Company is negotiating towards a settlement with the Department of Justice ("DOJ") of the USA for resolution of potential civil and criminal allegations by DOJ. Accordingly, the Company had recorded a provision of Rs. 26,480 (USD 500 Million) in the year ended 31 December 2011, which on a consideration of the progress in the matter so far, the Company believes will be sufficient to resolve all potential civil and criminal liability. The Company and its subsidiaries are in the process of negotiations which will conclusively pave the way for a Comprehensive DOJ Settlement. The settlement of this liability is expected to be made by the Company in compliance with the terms of settlement, once concluded and subject to other regulatory/ statutory provisions. Any gain/ loss on account of changes in exchange rate and related interest expense is presented in the relevant line items.
- 3 Changes in inventories of finished goods, work-in-progress and stock-in-trade for the quarter ended 31 March 2013 include prior period adjustment of Rs. 113.51.
- 4 Employee benefits expense for the quarter ended 31 March 2013 is net of Rs. 304.58 representing impact of revision in a defined benefit plan applicable to certain employees of the Company.
- 5 The amount represents foreign exchange gain/ (loss), net, on foreign currency option derivatives taken during previous years (other than option derivatives relating to loans) which are accounted in accordance with Accounting Standard 30, "Financial Instruments: Recognition and Measurement".
- 6 The research and development expenses is classified under respective heads of total expenses according to the nature of expense. The aggregate amount of such expenses (excluding finance costs, depreciation, amortisation and impairment) for all periods presented is set out below:

Particulars	(Unaudited) Quarter ended 31 March	(Audited) Quarter ended 31 December	(Unaudited) Quarter ended 31 March	(Audited) Year ended 31 December
	2013	2012	2012	2012
Research and development expenses	1,020.19	1,237.35	1,017.09	4,490.41

- 7 On exercise of Employees Stock Options, 94,136 equity shares have been allotted on 15 April 2013. The total number of Employees Stock Options outstanding as at 31 March 2013 were 6,857,495, out of which 4,500,128 have vested. The entitlement of shares on exercise of stock options granted on or before 3 October 2002 would increase in the proportion of 3:5, keeping in view the issue of bonus shares on 11 October 2002.
- 8 The Company's business activity falls within a single primary business segment viz. 'Pharmaceutical'.
- 9 Finance costs include exchange differences arising from foreign currency borrowings to the extent that they are regarded as an adjustment to interest costs. The aggregate amount of such exchange difference for all periods presented is set out below:

Particulars	(Unaudited) Quarter ended 31 March	(Audited) Quarter ended 31 December	(Unaudited) Quarter ended 31 March	(Audited) Year ended 31 December
	2013	2012	2012	2012
Foreign exchange loss/(gain)	12.70	819.59	(190.28)	1,239.74

- 10 Previous periods figures have been reclassified to conform to the current period's classification.
- 11 The above results were reviewed by the Audit Committee on 7 May 2013, and approved by the Board of Directors at their meeting held on 8 May 2013 and have undergone a "Limited Review" by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with the Bombay Stock Exchange and the National Stock Exchange and is also available on the Company's website at www.ranbaxy.com.

Place: Gurgaon
Date: 8 May 2013

By order of the Board


Arun Sawhney
CEO and Managing Director

Regd. Office : A-41, Industrial Area Phase VIII A, Sahibzada Ajit Singh Nagar (Mohali) - 160 071 (Punjab)

Website: <http://www.ranbaxy.com>